Fewer than one in 10 individuals eligible to benefit from obesity jabs such as Wegovy are able to get them, warns the global health agency as it releases its inaugural advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide now classified as obese, it is advocating for broader and more equitable access to these injectable treatments.
According to forecasts, in excess of 2,000,000,000 could be obese by 2030 unless action is taken.
"The latest guidelines recognises that excess weight is a long-term condition that can be treated with comprehensive and continuous support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and supply-chain constraints are major obstacles to broad access to the injections that can assist patients in reducing significant body mass, notes the body.
GLP-1 Therapy Shortage
Even under the present most optimistic case, the manufacturing of GLP-1 therapies could only cover about 100 million people – less than 10% of eligible patients, per the health organization.
The guideline calls on governments and firms to widen availability, through strategies like licensing agreements.
The intellectual property rights on semaglutide – the main component of a leading brand – is set to lapse in a number of nations in 2026.
The Way Obesity Drugs Function
GLP-1 drugs imitate a body's own hormone to slow digestion, curb appetite and increase satiety so users eat less.
People typically begin shedding pounds in the initial weeks of beginning the regular doses.
Research indicates people may see weight return within a year of discontinuing the treatment, when their usual hunger resume.
Being above a healthy weight increases your likelihood for developing medical conditions, including type 2 diabetes, cardiovascular issues, stroke, and some malignancies.
Excess weight affects people in all nations and was associated with millions of fatalities worldwide in 2024, according to the WHO.
